The extension sees Pfizer sign a five-year commercial agreement with CytoReason, which involves the former company paying a $90m (€90m) fee to gain access to the latter’s artificial intelligence technology. Pfizer will also make a $20m equity investment as part of the agreement. Beyond backing CytoReason financially, Pfizer also has the option to license the…
